ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / UFPT / forecast
INSP (65) XRAY (32) LMAT (67) KMTS (50) ⌘ Pro Terminal →

UFP Technologies Inc. (UFPT) 12-Month Stock Forecast & Price Target Cone

$283.97 -0.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $284.55

UFP Technologies Inc. (UFPT) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (28.3% gross margin, 14% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $2.20B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on UFPT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is UFPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, UFP Technologies Inc. (NASDAQ: UFPT) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $283.97 (-0.19% 1D, market cap $2.20B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, UFPT ranks #42 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does UFPT compare to INSP and XRAY in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), UFPT carries a Roarable B (74/100 RQD), trailing P/E of 33.3x, gross margin of 28.3%, and ROIC of 13.9%. By comparison, INSP (Inspire Medical Systems Inc.) holds a C grade (65/100 RQD, P/E 14.2x, ROIC 6.0%, cap $1.97B) and XRAY (DENTSPLY SIRONA Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -11.0%, cap $1.90B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for UFPT?
▼

Per UFPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000914156), UFP Technologies Inc. generated $602.8M in revenue (+19.5% YoY), $68.3M in net income, and $91.9M in free cash flow against $655.1M in total assets and $123.0M in total debt. Key quantitative strengths: Strong cash generator (28.3% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $284.57 (+0.21%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 15.2% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510074
2-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw B- · Rk B+
Cash (17)Whales (10)SEC (18)Macro (14)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+7.2% Base Target
$359 Bull$304 Base$233 Bear
📬 FREE UFPT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for UFPT)Realized 20D OHLCV Swing Band: ±6.9%
Deterministic 5-Pillar Attribution (74/100 Composite)
🔍 WHY UFPT SCORES 74/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (24% of score)

Altman Z-Score 8.31 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▲ #2 Bullish Driver: Cash Engine Quality+17/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 15.2% FCF Margin ($91.9M FCF) & 28.3% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning10/20 pts (-10 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-10 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
82
Grade A$294.29-1% Next Q
Q2 (-2Q)
79
Grade A-$291.34+1.2% Next Q
Q3 (-1Q)
77
Grade B+$294.84-3.7% Next Q
Current
74
Grade B$283.97+7.3% Hist 90D α
Trajectory: A (82) → B (74)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the UFPT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 74/100 (B) score, UFPT faces multiple-compression risk if 33.3x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 25.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($291.00) or 200D SMA ($249.56) invalidates the momentum regime and cuts Target Base ($304.42) toward Bear Floor ($232.86).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $UFPT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “UFPT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 74%NO 26%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your UFPT Position Size: $10,000

Shares at $283.97: 35.2 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $232.86
$8,200
$-1,800 (-18.0%)
12M Consensus BaseTarget $304.42
$10,720
+$720 (+7.2%)
12M Bull Case BreakoutTarget $359.22
$12,650
+$2,650 (+26.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (34 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 23● Hold: 9● Sell: 2
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskOUTPERFORM$31774%A
Goldman SachsSector Coverage LeadSTRONG BUY$33869%B
JP MorganUS Large-Cap ResearchHOLD$26958%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (UFPT Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
UFPT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +47.48%⚡ TESTING RESISTANCE
2026-11-03O $293.3H $293.3L $284.0C $284.0VOL 85.4K
RES: $297.2SUP: $281.1SMA50: $291.0SMA200: $249.6
$350.2$302.4$254.6$206.8$159.0RES $297.2SUP $281.1$284.02026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

UFPT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 UFPT Butterfly Map → + Track UFPT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
25.7%/yr Implied 5Y Growth

vs. +19.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on UFPT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for UFPT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for UFPT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (UFPT)

Health Care Rank #42 of 1015 ⚔️ INSP vs UFPT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (UFPT vs. INSP, XRAY, LMAT, KMTS)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, UFP Technologies Inc. (UFPT) ranks #42 by composite RQD confidence (74/100, grade B) and #240 by equity capitalization ($2.20B). Within this direct 5-issuer industry benchmark cohort, INSP leads on earnings valuation at 14.2x trailing P/E, while LMAT leads on capital efficiency and profitability with 14.7% ROIC and 71.5% gross margin. UFPT currently leads its immediate peer cohort in composite quantitative strength at 74/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
UFPT ACTIVE
UFP Technologies Inc.
B 74/100 33.3x 28.3% 13.9% -0.19% $2.20B Benchmark Subject
INSP
Inspire Medical Systems Inc.
C 65/100 14.2x 85.4% 6.0% -1.31% $1.97B /insp-vs-ufpt →
XRAY
DENTSPLY SIRONA Inc.
E 32/100 — 50.0% -11.0% +3.88% $1.90B /xray-vs-ufpt →
LMAT
LeMaitre Vascular Inc.
C+ 67/100 33.8x 71.5% 14.7% +0.40% $1.85B /lmat-vs-ufpt →
KMTS
Kestra Medical Technologies Ltd.
D 50/100 — 51.4% -35.0% +0.40% $1.77B /kmts-vs-ufpt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000914156 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), UFP Technologies Inc. (UFPT) reported GAAP revenue of $602.8M (+19.5% vs. FY2024 revenue of $504.4M , and +50.7% cumulative change since FY2023) , GAAP net income of $68.3M, operating cash flow of $91.9M, and free cash flow of $91.9M (+61.4% YoY). On the balance sheet, UFPT closed FY2025 with $655.1M in total assets against $123.0M in total debt (Altman Z-Score: 8.31, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $602.8M $68.3M $91.9M $91.9M $655.1M $123.0M
FY2024 (FY) 2024-12-31 $504.4M $59.0M $66.6M $56.9M $629.0M $176.9M
FY2023 (FY) 2023-12-31 $400.1M $44.9M $41.3M $41.3M — —

3. UFPT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is UFPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, UFP Technologies Inc. (NASDAQ: UFPT) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $283.97 (-0.19% 1D, market cap $2.20B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, UFPT ranks #42 in composite RQD confidence.

How does UFPT compare to INSP and XRAY in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), UFPT carries a Roarable B (74/100 RQD), trailing P/E of 33.3x, gross margin of 28.3%, and ROIC of 13.9%. By comparison, INSP (Inspire Medical Systems Inc.) holds a C grade (65/100 RQD, P/E 14.2x, ROIC 6.0%, cap $1.97B) and XRAY (DENTSPLY SIRONA Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -11.0%, cap $1.90B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for UFPT?

Per UFPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000914156), UFP Technologies Inc. generated $602.8M in revenue (+19.5% YoY), $68.3M in net income, and $91.9M in free cash flow against $655.1M in total assets and $123.0M in total debt. Key quantitative strengths: Strong cash generator (28.3% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is UFPT trading relative to its 50-day, 200-day, and 52-week technical levels?

UFPT last traded at $283.97 (-0.19% on volume of 85,502 shares), positioning the stock -2.42% below its 50-day simple moving average ($291.00) and +13.79% above its 200-day simple moving average ($249.56). Across its 52-week range of $173.86 to $338.71, UFPT sits at the 66.8% percentile with a 14-day RSI of 45.0 (NEUTRAL RANGE) and an implied next-earnings move of ±6.9% ($264.38 to $303.56).

Direct Sub-Reports: UFPT RQD Cockpit UFPT 12M Forecast UFPT Earnings & Move UFPT Dividends & DRIP UFPT Insiders & 13F UFPT Whale Options UFPT Profit Sankey UFPT News & Why
ROARABLE RATING BRIEF • RQD 74/100 (B) ✓ SEC XBRL & RQD VERIFIED

UFPT — UFP Technologies Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

UFP Technologies Inc. (UFPT) earns a live Roarable RQD composite score of 74/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $283.97 (-0.19% 1D, market capitalization $2.20B).

  • Fundamental Cash Engine (17/20): Anchored by return on invested capital (ROIC) of 13.9%, gross margin of 28.3%, operating margin of 15.3%, and free cash flow yield of 4.05%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (14/20) + Forensic Balance Sheet (18/20): Incorporates a 1.00x equity beta, Altman Z-Score of 8.31, Piotroski F-Score of 9/9, and Debt/Equity of 0.29x.

2. Business Model, Unit Margins & SEC Financial Trajectory

UFP Technologies Inc. (UFPT) is a NASDAQ-listed issuer in the Health Care sector and the Medical/Dental Instruments industry. The company carries a market capitalization of $2.3B. — for specific product lines, customer base, or revenue model detail.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), UFP Technologies Inc. (UFPT) reported $602.8M in annual revenue (up from $504.4M in FY2024, +19.5% YoY) and $68.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($400.1M revenue, $44.9M net income) through FY2025, UFPT scaled operating cash flow to $91.9M and free cash flow to $91.9M, backed by $655.1M in total assets against $123.0M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B • RQD 74/100): Strong cash generator (28.3% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 17/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $173.86 – $338.71 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 33.3x trailing P/E and 25.7x EV/EBITDA against 15.3% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— there are no upstream or downstream links, no sector correlations, and no proprietary signals recorded. The Health Care / Medical-Dental Instruments classification is noted, but no ripple mapping is provided.

  • Key Question #1: Can UFPT sustain or expand its 15.3% operating margin and 13.9% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $602.8M and free cash flow of $91.9M, how will capital allocation balance growth reinvestment against $123.0M in total debt?
  • Key Question #3: How sensitive is UFPT's 28.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

UFPT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for UFP Technologies Inc. (UFPT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to UFPT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

UFPT Bull vs. Bear Conversation Board — What's Your Call at $283.97?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON UFPT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on UFPT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $335.71 (+18.0%)
📌 Pinned Debate

Revenue grew from $400.1M to $602.8M in two years while the balance sheet strengthened, with Piotroski F-Score 9/9 and Altman Z-Score 8

Here is why I am bullish on UFPT here at $284.50: Revenue grew from $400.1M to $602.8M in two years while the balance sheet strengthened, with Piotroski F-Score 9/9 and Altman Z-Score 8.31.. Compare UFPT's 15.3% operating margin and 13.9% ROIC against the rest of Medical/Dental Instruments. As long as cash conversion holds up, dips toward $270.27 are getting bought.

SectorRotator 🐂 BULL

@QuantViper Agree on the RQD 74/100 quality, though with 1.0 beta I'm scaling in with half-size at $284.50 and keeping dry powder in case we test $264.59.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $224.76 (-21.0%)
Spot @ $284.50

At a P/E (TTM) of 33.3 and EV/EBITDA of 25.7 against a 4.05% FCF yield, the valuation prices in continued growth with little margin for

Sitting on the sidelines or leaning short UFPT above $284.50. At a P/E (TTM) of 33.3 and EV/EBITDA of 25.7 against a 4.05% FCF yield, the valuation prices in continued growth with little margin for error.. Until Fundamental Cash Engine (17/20) and FCF yield (4.05%) inflect higher, upside is capped near $338.71.

LIVE TAPE